Market Access News | pharmaphorum

News

Tarsus gets first FDA nod for mite blepharitis therapy

A common eyelid disease caused by infestation with tiny parasitic mites that live in hair follicles now has its first approved treatment in the US.<

News

EMA panel rejects Mirati’s KRAS drug Krazati

Mirati Therapeutics’ hopes of an EU approval for its KRAS inhibitor Krazati in the EU have been thrown into disarray after the EMA’s human medicines committee rejected the

News

AbbVie nears EU nod for DLBCL drug epcoritamab

AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an a

News

FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years a

News

ABPI slams UK government consultation on drug levy

For all the UK government’s rhetoric on supporting the life sciences industry, it seems destined to alienate the very sector it is trying to court.

News

New HTA body pledges to ‘cut the hype’ in digital health

US non-profit the Peterson Centre on Healthcare has launched a new institute, backed with $50 million in funding, that will take a close look at the clinical benefits and

Tarsus gets first FDA nod for mite blepharitis therapy

EMA panel rejects Mirati’s KRAS drug Krazati

AbbVie nears EU nod for DLBCL drug epcoritamab

FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

ABPI slams UK government consultation on drug levy

New HTA body pledges to ‘cut the hype’ in digital health

GSK to quit Stevenage for new R&D site in Cambridge

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks